Patents by Inventor Per Hertz Hansen
Per Hertz Hansen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110124556Abstract: Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, certain of the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonists may also be developed as therapeutics.Type: ApplicationFiled: April 20, 2010Publication date: May 26, 2011Applicants: NOVO NORDISK A/S, ANTYRA INC.Inventors: RENUKA PILLUTLA, RENEE BRISSETTE, ARTHUR J. BLUME, LAUGE SCHAFFER, JAKOB BRANDT, NEIL I. GOLDSTEIN, JANE SPETZLER, SOREN OSTERGAARD, PER HERTZ HANSEN
-
Patent number: 7576059Abstract: A pharmacologically active peptide hormone derivative in which the parent peptide hormone has been modified by introducing either a lipophilic substituent, W, in the N-terminal amino acid or a lipophilic substituent, Z, in the C-terminal amino acid of the parent peptide hormone or an analogue thereof, said lipophilic substituent having from 8 to 40 carbon atoms, has a protracted profile of action.Type: GrantFiled: January 30, 2001Date of Patent: August 18, 2009Assignee: Novo Nordisk A/SInventors: Ib Jonassen, Svend Havelund, Per Hertz Hansen, Peter Kurtzhals, John B. Halstrøm
-
Publication number: 20090192072Abstract: Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, certain of the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonists may also be developed as therapeutics.Type: ApplicationFiled: November 21, 2008Publication date: July 30, 2009Applicants: Novo Nordisk A/S, Antyra Inc. (formerly DGI Bio Technologies)Inventors: Renuka Pillutla, Renee Brissette, Arthur J. Blume, Lauge Schaffer, Jacob Brandt, Neil I. Goldstein, Jane Spetzler, Soren Ostergaard, Per Hertz Hansen
-
Patent number: 7229964Abstract: The present invention relates to insulin derivatives in which a lipophilic group having from 12 to 40 carbon atoms is attached to the ?-amino group of the N-terminal amino acid in the B-chain or to the carboxy group of the C-terminal amino acid in the B-chain have a protracted profile of action.Type: GrantFiled: July 16, 2003Date of Patent: June 12, 2007Assignee: Novo Nordisk A/SInventors: Jan Markussen, Ib Jonassen, Svend Havelund, Jakob Brandt, Peter Kurtzhals, Per Hertz Hansen, Niels Christian Kaarsholm
-
Patent number: 6875741Abstract: Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, certain of the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonists may also be developed as therapeutics.Type: GrantFiled: September 24, 2001Date of Patent: April 5, 2005Inventors: Renuka Pillutla, Renee Brissette, Arthur J. Blume, Lauge Schäffer, Jakob Brandt, Neil I. Goldstein, Jane Spetzler, Søren Østergaard, Per Hertz Hansen
-
Publication number: 20040067874Abstract: The present invention relates to insulin derivatives in which a lipophilic group having from 12 to 40 carbon atoms is attached to the &agr;-amino group of the N-terminal amino acid in the B-chain or to the carboxy group of the C-terminal amino acid in the B-chain have a protracted profile of action.Type: ApplicationFiled: July 16, 2003Publication date: April 8, 2004Inventors: Jan Markussen, Ib Jonassen, Svend Havelund, Jakob Brandt, Peter Kurtzhals, Per Hertz Hansen, Niels Christian Kaarsholm
-
Publication number: 20030236190Abstract: Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, certain of the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonists may also be developed as therapeutics.Type: ApplicationFiled: September 24, 2002Publication date: December 25, 2003Inventors: Renuka Pillutla, Renee Brissette, Arthur J. Blume, Lauge Schaffer, Jacob Brandt, Neil I. Goldstein, Jane Spetzler, Soren Ostergaard, Per Hertz Hansen
-
Publication number: 20030195147Abstract: Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, certain of the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonists may also be developed as therapeutics.Type: ApplicationFiled: September 24, 2001Publication date: October 16, 2003Inventors: Renuka Pillutla, Renee Brissette, Arthur J. Blume, Lauge Schaffer, Jakob Brandt, Neil I. Goldstein, Jane Spetzler, Soren Ostergaard, Per Hertz Hansen
-
Patent number: 6620780Abstract: The present invention relates to insulin derivatives in which a lipophilic group having from 12 to 40 carbon atoms is attached to the &agr;-amino group of the N-terminal amino acid in the B-chain or to the carboxy group of the C-terminal amino acid in the B-chain have a protracted profile of action.Type: GrantFiled: May 21, 2001Date of Patent: September 16, 2003Assignee: Novo Nordisk A/SInventors: Jan Markussen, Ib Jonassen, Svend Havelund, Jakob Brandt, Peter Kurtzhals, Per Hertz Hansen, Niels Christian Kaarsholm
-
Publication number: 20020193292Abstract: The present invention relates to insulin derivatives in which a lipophilic group having from 12 to 40 carbon atoms is attached to the &agr;-amino group of the N-terminal amino acid in the B-chain or to the carboxy group of the C-terminal amino acid in the B-chain have a protracted profile of action.Type: ApplicationFiled: May 21, 2001Publication date: December 19, 2002Inventors: Jan Markussen, Ib Jonassen, Svend Havelund, Jakob Brandt, Peter Kurtzhals, Per Hertz Hansen, Niels Christian Kaarsholm
-
Publication number: 20010016643Abstract: A pharmacologically active peptide hormone derivative in which the parent peptide hormone has been modified by introducing either a lipophilic substituent, W, in the N-terminal amino acid or a lipophilic substituent, Z, in the C-terminal amino acid of the parent peptide hormone or an analogue thereof, said lipophilic substituent having from 8 to 40 carbon atoms, has a protracted profile of action.Type: ApplicationFiled: January 30, 2001Publication date: August 23, 2001Inventors: Ib Jonassen, Svend Havelund, Per Hertz Hansen, Peter Kurtzhals, John B. Halstrom
-
Patent number: 6251856Abstract: The present invention relates to insulin derivatives in which a lipophilic group having from 12 to 40 carbon atoms is attached to the &agr;-amino group of the N-terminal amino acid in the B-chain or to the carboxy group of the C-terminal amino acid in the B-chain have a protracted profile of action.Type: GrantFiled: September 17, 1997Date of Patent: June 26, 2001Assignee: Novo Nordisk A/SInventors: Jan Markussen, Ib Jonassen, Svend Havelund, Jakob Brandt, Peter Kurtzhals, Per Hertz Hansen, Niels Christian Kaarsholm
-
Patent number: 5869602Abstract: The present invention relates to a pharmacologically active peptide hormone derivative in which the parent peptide hormone has been modified by introducing either a lipophilic substituent, W, in the N-terminal amino acid or a lipophilic substituent, Z, in the C-terminal amino acid of the parent peptide hormone or an analogue thereof, said lipophilic substituent having from 8 to 40 carbon atoms, has a protracted profile of action.Type: GrantFiled: May 23, 1995Date of Patent: February 9, 1999Assignee: Novo Nordisk A/SInventors: Ib Jonassen, Svend Havelund, Per Hertz Hansen, Peter Kurtzhals, John Halstr.o slashed.m